JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 650 from DKK 1,000 and keeps an Overweight rating on the shares.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Advances Amycretin to Phase 3 for Weight Management
- Novo Nordisk to advance subcutaneous and oral amycretin for weight management
- Novo Nordisk call volume above normal and directionally bullish
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories
- Nvidia partners with Novo Nordisk to accelerate drug discovery